Browse UCHL1

Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Endoplasmic reticulum membrane Lipid-anchor Note=About 30% of total UCHL1 is associated with membranes in brain.
Domain PF01088 Ubiquitin carboxyl-terminal hydrolase
Function

Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0002931 response to ischemia
GO:0006469 negative regulation of protein kinase activity
GO:0006914 autophagy
GO:0007018 microtubule-based movement
GO:0007409 axonogenesis
GO:0007412 axon target recognition
GO:0007626 locomotory behavior
GO:0007628 adult walking behavior
GO:0007631 feeding behavior
GO:0008088 axo-dendritic transport
GO:0008344 adult locomotory behavior
GO:0010498 proteasomal protein catabolic process
GO:0010506 regulation of autophagy
GO:0010970 transport along microtubule
GO:0016236 macroautophagy
GO:0016241 regulation of macroautophagy
GO:0016579 protein deubiquitination
GO:0019233 sensory perception of pain
GO:0019896 axonal transport of mitochondrion
GO:0030534 adult behavior
GO:0030705 cytoskeleton-dependent intracellular transport
GO:0033673 negative regulation of kinase activity
GO:0034643 establishment of mitochondrion localization, microtubule-mediated
GO:0042326 negative regulation of phosphorylation
GO:0042692 muscle cell differentiation
GO:0042755 eating behavior
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0044708 single-organism behavior
GO:0047497 mitochondrion transport along microtubule
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048747 muscle fiber development
GO:0050905 neuromuscular process
GO:0051146 striated muscle cell differentiation
GO:0051348 negative regulation of transferase activity
GO:0051640 organelle localization
GO:0051646 mitochondrion localization
GO:0051654 establishment of mitochondrion localization
GO:0051656 establishment of organelle localization
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0061564 axon development
GO:0070646 protein modification by small protein removal
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0072384 organelle transport along microtubule
GO:0090659 walking behavior
GO:0098930 axonal transport
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004175 endopeptidase activity
GO:0004197 cysteine-type endopeptidase activity
GO:0004843 thiol-dependent ubiquitin-specific protease activity
GO:0008234 cysteine-type peptidase activity
GO:0008238 exopeptidase activity
GO:0008242 omega peptidase activity
GO:0016874 ligase activity
GO:0019783 ubiquitin-like protein-specific protease activity
GO:0031625 ubiquitin protein ligase binding
GO:0031690 adrenergic receptor binding
GO:0031694 alpha-2A adrenergic receptor binding
GO:0032182 ubiquitin-like protein binding
GO:0036459 thiol-dependent ubiquitinyl hydrolase activity
GO:0043130 ubiquitin binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0101005 ubiquitinyl hydrolase activity
Cellular Component GO:0030424 axon
GO:0032838 cell projection cytoplasm
GO:0033267 axon part
GO:0043025 neuronal cell body
GO:0043209 myelin sheath
GO:0044297 cell body
GO:0044306 neuron projection terminus
GO:0099568 cytoplasmic region
GO:1904115 axon cytoplasm
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-5689603: UCH proteinases
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UCHL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UCHL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UCHL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.5980.0287
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.4530.0911
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9840.446
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2620.65
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3040.805
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9730.525
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.70.253
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5010.638
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0640.395
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0090.997
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.3080.706
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2770.319
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UCHL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UCHL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UCHL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UCHL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UCHL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UCHL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UCHL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUCHL1
Nameubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Aliases PGP9.5; Uch-L1; PARK5; HEL-117; NDGOA; PGP 9.5; PGP95; neuron cytoplasmic protein 9.5; ubiquitin C-terminal ......
Chromosomal Location4p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UCHL1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting UCHL1.
ID Name Drug Type Targets #Targets
DB12695Phenethyl IsothiocyanateSmall MoleculeACTA2, ACTB, ATP5B, ATP5I, ATP5L, CYB5B, DIABLO, FBXO41, HNRNPF, H ......45